02 March 2019 | Bern
Update in Genitourinary Cancers
09:00–09:10 Welcome & Start of the program
Jörg Beyer

09:10–10:10 Prostate Cancer
Chair: Aurelius Omlin
- Martin Spahn: Diagnostic procedures in prostate cancer diagnosis: State-of-the-art
- Andrew Vickers: PSA screening – towards a harm reduction approach
- Samir Taneja: The role of MRI in target biopsy
- Scott Williams: A randomized trial comparing fluorochrome-PET/CT with conventional imaging in prostate cancer

10:10–10:30 Break

10:30–12:30 Prostate Cancer
Chair: Martin Spahn
- Aurelius Omlin: Controversies in PCa
- Nicolas J. Van As: PACE: Analysis of acute toxicity in PACE-B, an international phase II randomized controlled trial comparing stereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately hypofractionated external beam radiotherapy (CFMHRT) for localized prostate cancer (LPCa).
- Andrew J. Armstrong: 3 phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ERZ) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial.
- Karim Fizazi: ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC).
- Evan Yu: Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).

12:30–13:00 Lunch

13:30–16:00 Urothelial Bladder Cancer
Chair: Dominik Berthold
- Jörg Beyer: What are the issues in localized urothelial bladder cancer?
- Michael Cookson: Radical Cystectomy is the Best Option for Muscle-Invasive Bladder Cancer
- Jason A. Efstathiou: Trimodality Therapy is the Best Option for Muscle-Invasive Bladder Cancer
- Andrea Necchi: Perioperative immunotherapy in Urothelial Carcinomas: State of Existing Evidence
- James L. Gulley: Key Note Lecture: Immunotherapy Across Genitourinary Malignancies

16:00–16:30 Break

16:30–18:00 Renal Cancer
Chair: Jörg Beyer
- Dominik Berthold: New standard in RCC: TKI, Immunotherapy or both
- Brian M. Shuch: When to Obtain Genetic Testing for Syndromic Renal Cell Cancer
- Paul Russo: Lessons learned from Carisrama: Surgeon’s Perspective
- Laureen C. Marshman: Lessons learned from Carisroma: Medical Oncologist’s Perspective
- Thomas Powles: Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phaseIII KEYNOTE-426 study
- Daniel Y. C. Meng: Beyond First-Line Systemic Therapy for Metastatic Renal Cell Cancer

18:00–18:20 Important trials and activities in Switzerland in urogenital cancer in 2018
- Aurelius Omlin: Prostate Cancer (5 min)
- Martin Spahn: Urothelial bladder Cancer (5 min)
- Jörg Beyer: Testicular Cancer (5 min)
- Dominik Berthold: Renal Cell Cancer (5 min)

18:20–18:30 Closing Remarks
The ASCO Direct GU Highlights Meeting is a full-day educational program containing selected original sessions from the 2019 Genitourinary Cancers Symposium on urothelial carcinoma, prostate, bladder, renal, penile, urethral, and testicular cancers.

You will have the opportunity to view the original sessions and discuss the clinical relevance and implications for Swiss treatment landscape of study outcomes with your colleagues.

The program is developed by an independent scientific committee:

- Jörg Beyer, Inselspital Bern
- Martin Spahn, Hirslanden
- Aurelius Omlin, Kantonsspital St. Gallen
- Dominik Berthold, Centre Hospitalier Universitaire Vaudois

Register now: medicinematters.com/ascodirectgu/switzerland/
Registration fee (115 CHF) will be donated to Movember Foundation

ASCO Direct™ Highlights is an officially licensed program of the American Society of Clinical Oncology®. ASCO® is a registered trademark of the American Society of Clinical Oncology. All rights reserved. ASCO® does not endorse any health care product, therapy, diagnostic test or device.